Abstract
The ability of bromocriptine (BRC), a selective dopamine D-2 receptor agonist, to induce yawning responses was studied in rats pretreated with reserpine and α-methyl-p-tyrosine (α-MPT). BRC (1–20 mg/kg IP) evoked yawning responses, which were pronounced at 2.5 mg/kg and characterized by the head moving downward. Higher doses of BRC (5–20 mg/kg) dose-dependently delayed the onset and peak time of yawning. A low dose of the selective D-1 dopamine receptor agonist SK&F38393 did not induce yawning but enhanced the BRC-induced response. Pretreatment with reserpine (1 and 5 mg/kg SC), α-MPT (100 and 300 mg/kg IP) and reserpine (1 mg/kg) plus α-MPT (100 mg/kg) was able to significantly reduce BRC-induced yawning. The inhibitory effects were prevented by a low dose of SK&F38393 (0.5 mg/kg IP). In particular, combined treatment with reserpine (5 mg/kg) and BRC (10 and 20 mg/kg) elicited upright fighting and jumping behaviors which were inhibited by haloperidol (1 mg/kg IP), a non-selective D-1 and D-2 receptor antagonist, SCH23390 (0.05 mg/kg SC), a selective D-1 receptor antagonist, or sulpiride (20 mg/kg IP), a potent D-2 receptor antagonist, and were potentiated by SK&F38393 (0.5 mg/kg). SCH23390 (0.05 mg/kg) decreased BRC-induced yawning and the apomorphine (low doses)-induced potentiation of BRC yawning, and prevented the apomorphine (high doses)-induced reduction of BRC yawning. SCH23390 also inhibited apomorphine-induced stereotypy and BRC-induced potentiation of apomorphine stereotypy. Furthermore, haloperidol (0.02 and 1.0 mg/kg IP), sulpiride (20 mg/kg IP) or scopolamine (0.5 mg/kg IP) inhibited BRC-induced yawning, but prazosin (1.0 and 3.0 mg/kg IP), an α-1 receptor antagonist, did not affect this behavior. These results suggest that BRC-induced yawning may be mediated via presynaptic dopaminergic neuron activity and that BRC, in addition to the stimulation of dopamine D-2 receptors, appears to require endogenous dopamine or receptor activation by another dopamine agonist (D-1 agonist) for the induction of yawning, stereotypy and upright fighting responses. The ability of dopamine agonists to induce these behaviors seems to depend apon the potency and ratio of D-2 versus D-1 receptor activity.
Similar content being viewed by others
References
Arnt J, Hyttel J, Perregaard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirol facilitate the expression of oral stereotyped behavior in rats. Eur J Pharmacol 133:137–145
Benkert O, Gluba H, Matussek N (1973) Dopamine, noradrenaline and 5-hydroxytryptamine in relation to motor activity, fighting and mounting behavior. I. l-dopa and dl-threo-dihydroxyphenylserine in combination with Ro4–4602, pargyline and reserpine. Neuropharmacology 12:177–186
Bergh T, Nillius SJ, Wide L (1978) Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol (Copenh) 88:435–451
Carlsson A (1975) Receptor-mediated control of dopamine metabolism. In: Usdin E, Bunny WE (eds) Pre- and postsynaptic receptor. Dekker, New York, pp 49–65
Gessa GL, Porceddu ML, Collu M, Mereu G, Serra M, Ongini E, Biggio G (1985) Sedation and sleep induced by high doses of apomorphine after blockade of D-1 receptors by SCH 23390. Eur J Pharmacol 109:269–274
Goldstein M, Lew JY, Hata F, Lieberman A (1978) Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontologie [Suppl 1] 24:76–85
Gonzalez-Lima F, Stiehl WL, Medina R (1984) Long-lasting behavioral effects of bromocriptine in cats. Eur J Pharmacol 102:279–287
Groves PM, Wilson CJ, Young SJ, Rebec GV (1975) Self-inhibition by dopaminergic neurons: an alternative to the “neuronal feedback loop” hypothesis for the mode of action of certain psychotropic drugs. Science 190:522–529
Hyttel J (1983) SCH 23390, the first selective dopamine D-1 antagonist. Eur J Pharmacol 91:153–154
Jenkins OF, Jackson DM (1985) Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice. Naunyn-Schmiedeberg's Arch Pharmacol 331:7–11
Johnson AM, Loew DM, Vigouret JM (1976) Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and l-dopa. Br J Pharmacol 56:59–68
Lammers AJJC, Van Rossum JM (1968) Bizarre social behaviour in rats induced by a combination of a peripheral decarboxylase inhibitor and dopa. Eur J Pharmacol 5:103–106
Lieberman A, Zolfaghari M, Boal D, Hassan H, Vogel B, Battista H, Foxe K, Goldstein M (1976) The antiparkinson efficacy of bromocriptine. Neurology 26:405–409
Mogilnicka E, Klimek V (1977) Drugs affecting dopamine neurons and yawning behaviour. Pharmacol Biochem Behav 7:303–305
Morelli M, Longoni R, Spina L, Di Chiara G (1986) Antagonism of apomorphine-induced yawning by SCH 23390: evidence against the autoreceptor hypothesis. Psychopharmacology 89:259–260
Protais P, Dubuc I, Contentin J (1983) Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behavior in rats. Eur J Pharmacol 94:271–280
Robertson A, MacDonald C (1985) Opposite effects of sulpiride and metoclopramide on amphetamine-induced stereotypy. Eur J Pharmacol 109:81–89
Spano PF, Trabucchi M (1978) Interaction of ergot alkaloids with dopaminergic receptors in rat striatum and nucleus accumbens. Gerontology [Suppl 1] 24:106–114
Trabucchi M, Cheney GL, Racagni G, Costa E (1975) In vivo inhibition of striatal acetylcholine turnover by l-dopa, apomorphine and (+)-amphetamine. Brain Res 85:130–134
Trabucchi M, Hofman M, Montefusco O, Spano PF (1978) Ergot alkaloids and cyclic nucleotides in the CNS. Pharmacology [Suppl 1] 16:150–155
Ushijima I, Mizuki Y, Imaizumi J, Yamada Y, Noda Y (1985) Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine. Arch Int Pharmacodyn 273:196–201
Ushijima I, Mizuki Y, Soeda K, Kishimoto O, Hara T, Yamada M (1987) Effects of age on behavioral responses to dopamine agonists in the rat. Eur J Pharmacol 138:101–106
Ushijima I, Mizuki Y, Yamada M (1988) Multifocal sites of action involved in dopaminergic-cholinergic neuronal interaction in yawning. Psychopharmacology 95:34–37
Yamada K, Furukawa T (1980) Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology 67:39–43
Yamada K, Furukawa T (1981) The yawning elicited by α-melanocyte-stimulating hormone involves serotonergic-dopaminergic-cholinergic neuron link in rats. Nawnyn-Schmiedeberg's Arch Pharmacol 316:155–160
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ushijima, I., Mizuki, Y. & Yamada, M. The mode of action of bromocriptine following pretreatment with reserpine and α-methyl-p-tyrosine in rats. Psychopharmacology 95, 29–33 (1988). https://doi.org/10.1007/BF00212761
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00212761